Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Graybug Vision  (Stock symbol: GRAY )

275 Shoreline Dr #450
Redwood city, CA 94065
USA
(650) 487-2800
Website Company Summary Management Team
Management

CEO: Frederic Guerard (2/28/2019)
President/COO/Operations: Dan Salain (12/31/2017)
General Management: Jinzhong Zhang (2018) ; Karl G. Trass ; Valerie Smith (5/31/2017)
Finance: Han Wettenstein (8/31/2018) ; Pamela M. Wapnick (12/31/2017) ; Robert S. Breuil (9/1/2020)
Technology: Rajendra Mohabir ; Ming Yang (4/30/2014)
Former Employees: Charles Semba Jeffrey L. Cleland
Board

Outside board: (May no longer be on the board) Gerald G. Cagle (Alcon Former Chief Scientific Officer) Emmett Cunningham (Clarus Ventures Partner) Chau Q. Khuong (OrbiMed Private Equity Partner) Michael Keyoung (CBC Group Managing Director) Justin Hanes (Johns Hopkins University School of Medicine Professor of Ophthalmology) Cameron Wheeler (Deerfield Principal) Christy L. Shaffer (Burroughs Wellcome Associate Director of Pulmonary and Critical Care Medicine)
Company

Business description: Graybug Vision is a clinical-stage pharmaceutical company focused on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. To address the burden of frequent intravitreal injections associated with managing patients with neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vascular occlusive disease (RVO), Graybug Vision is developing a proprietary depot formulation of sunitinib malate, GB-102. Sunitinib inhibits multiple biologic pathways known to be associated with angiogenesis, vascular permeability, fibrosis, while promoting neuroprotection to retinal ganglion cells and photoreceptors. To address the low compliance rate of self-administered eye drops for the treatment of elevated intraocular pressure (IOP) associated with primary open-angle glaucoma (POAG) and ocular hypertension (OHT), Graybug Vision is developing novel injectable compounds that will allow the physician to manage the pharmacologic treatment of disease rather than the patient. The company has established a portfolio of over 100 proprietary compounds to lower IOP and / or provide neuroprotection.
Capital

Rounds: 3
Recent Fundings: Aug 2019   May 2016
Capital raised: 124.5M
Last Round: 80.0M
Ownership: Public   Ipo Filing
Stock Symbol: GRAY
VCs include: OrbiMed Clarus Ventures ;  Hatteras Venture Partners ;  Deerfield Management Company ;  CBC Group

Last Tweets


 

Last Mentions


Overview
Record updated: Sep 2020
Sector: Medical
Headcount: 26-50 as of Sep 2020
Rounds: 3
Recent Fundings: Aug 2019   May 2016
Capital Raised: 124.5M
Last Round: 80.0M
Ownership: Public   Ipo Filing
Stock Symbol: GRAY